Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2

[1]  Yufeng Yao,et al.  S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants , 2023, Vaccines.

[2]  R. Webby,et al.  Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents , 2022, Nature.

[3]  A. Gamarnik,et al.  Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern , 2022, Frontiers in Immunology.

[4]  A. Sette,et al.  Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines , 2022, Immunological reviews.

[5]  B. Pulendran,et al.  Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice , 2022, NPJ vaccines.

[6]  A. Di Pietro,et al.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives , 2022, Vaccines.

[7]  Suh-Chin Wu,et al.  Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity , 2022, International journal of molecular sciences.

[8]  Xing Wu,et al.  Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates , 2022, Signal Transduction and Targeted Therapy.

[9]  M. Koopmans,et al.  Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients , 2022, Science Immunology.

[10]  D. Barouch,et al.  Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron , 2022, Nature.

[11]  A. Sette,et al.  T cell responses to SARS-CoV-2 spike cross-recognize Omicron , 2022, Nature.

[12]  S. Mallal,et al.  SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron , 2022, Cell.

[13]  D. Sather,et al.  Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus , 2021, PLoS biology.

[14]  Katherine V Chew,et al.  An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice , 2021, Science Translational Medicine.

[15]  B. Akache,et al.  Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant , 2021, Scientific Reports.

[16]  Aaron M. Rosenfeld,et al.  Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses , 2021, Immunity.

[17]  Cunbao Liu,et al.  An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines , 2021, Vaccines.

[18]  B. Pulendran,et al.  Hydrogel‐Based Slow Release of a Receptor‐Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS‐CoV‐2 , 2021, Advanced materials.

[19]  W. Kong,et al.  Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants. , 2021, International immunopharmacology.

[20]  M. Cascalho,et al.  A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine , 2021, Frontiers in Immunology.

[21]  J. Tregoning,et al.  Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[22]  Huachen Zhu,et al.  A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters , 2021, Science Translational Medicine.

[23]  Jennifer S. Wood,et al.  A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates , 2021, Science Immunology.

[24]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[25]  S. Madhi,et al.  Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum , 2021, Cell.

[26]  Lisa E. Gralinski,et al.  SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung , 2021, Nature Communications.

[27]  B. Pulendran,et al.  Emerging concepts in the science of vaccine adjuvants , 2021, Nature reviews. Drug discovery.

[28]  N. Patel,et al.  SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.

[29]  J. Jan,et al.  CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge , 2021, Scientific Reports.

[30]  Lisa E. Gralinski,et al.  SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo , 2020, Science.

[31]  F. Krammer.  SARS-CoV-2 vaccines in development , 2020, Nature.

[32]  N. Patel,et al.  NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.

[33]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[34]  Ilya J. Finkelstein,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[35]  Xuguang Li,et al.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity , 2020, Cell.

[36]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[37]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[38]  W. Schrödl,et al.  Comparative analysis of humoral immune responses and pathologies of BALB/c and C57BL/6 wildtype mice experimentally infected with a highly virulent Rodentibacter pneumotropicus (Pasteurella pneumotropica) strain , 2018, BMC Microbiology.

[39]  B. Ward,et al.  Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice. , 2016, Vaccine.

[40]  M. Glennie,et al.  Influence of immunoglobulin isotype on therapeutic antibody function. , 2016, Blood.

[41]  M. Boxus,et al.  Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine , 2016, Human vaccines & immunotherapeutics.

[42]  Jinfang Zhu.  T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. , 2015, Cytokine.

[43]  B. Ward,et al.  AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice , 2015, Front. Immunol..

[44]  P. Chomez,et al.  Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. , 2011, Vaccine.

[45]  E. Agger,et al.  T‐helper 1 and T‐helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection , 2010, Immunology.

[46]  C. Xiao,et al.  Adjuvant effects of saponins on animal immune responses , 2007, Journal of Zhejiang University SCIENCE B.

[47]  E. B. Lindblad.  Aluminium compounds for use in vaccines , 2004, Immunology and cell biology.

[48]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[49]  G. Plosker,et al.  Prepandemic Influenza Vaccine H5N1 (Split Virion, Inactivated, Adjuvanted) [Prepandrix™] , 2012, BioDrugs.

[50]  C. Kensil.  Saponins as vaccine adjuvants. , 1996, Critical reviews in therapeutic drug carrier systems.